Walt D. has taken KESIMPTA and has been compensated for his time. For adults only.
*Once monthly after 3 weekly starter doses.
†Reduced annual rate of relapses by 51% and 58%, reduced average number of Gd+ T1 lesions per MRI by 98% and 94%,
reduced disability progression by 34% at 3 months and 32% at 6 months in 2 studies vs AUBAGIO.
*Once monthly after 3 weekly starter doses.
†Reduced annual rate of relapses by 51% and 58%, reduced average number of
Gd+ T1 lesions per MRI by 98% and 94%,
reduced disability progression by 34% at
3 months and 32% at 6 months in 2 studies vs AUBAGIO.